9jky: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
m Protected "9jky" [edit=sysop:move=sysop]
OCA (talk | contribs)
No edit summary
 
Line 1: Line 1:
'''Unreleased structure'''


The entry 9jky is ON HOLD
==acifran-HCAR2-Gi complex==
 
<StructureSection load='9jky' size='340' side='right'caption='[[9jky]], [[Resolution|resolution]] 2.72&Aring;' scene=''>
Authors: Binghao, Z., Fang, Y.
== Structural highlights ==
 
<table><tr><td colspan='2'>[[9jky]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9JKY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9JKY FirstGlance]. <br>
Description: acifran-HCAR2-Gi complex
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 2.72&#8491;</td></tr>
[[Category: Unreleased Structures]]
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=P9X:(5~{S})-5-methyl-4-oxidanylidene-5-phenyl-furan-2-carboxylic+acid'>P9X</scene></td></tr>
[[Category: Fang, Y]]
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9jky FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9jky OCA], [https://pdbe.org/9jky PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9jky RCSB], [https://www.ebi.ac.uk/pdbsum/9jky PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9jky ProSAT]</span></td></tr>
[[Category: Binghao, Z]]
</table>
== Function ==
[https://www.uniprot.org/uniprot/HCAR2_HUMAN HCAR2_HUMAN] Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.<ref>PMID:17932499</ref>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Binghao Z]]
[[Category: Fang Y]]

Latest revision as of 07:14, 29 October 2025

acifran-HCAR2-Gi complex

9jky, resolution 2.72Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA